new guidance

New steps to facilitate efficient generic drug review in FDA

New guidances help ANDA applicants avoid common deficiencies

New guidances help ANDA applicants avoid common deficiencies
January 10, 2018

The US Agency released two documents aimed at improving aspects of the submission and review of generic drug applications. The new guidances for ANDA applications are:

Usually generic approvals are delayed as many applications undergo multiple review cycles. This guidance points out frequent deficiencies of ANDA procedures and makes recommendations on how to avoid them in order to minimise the number of review cycles necessary for approval.

It comprises internal practices and procedures followed by CDER to help standardise the drug review process and other activities, both internal and external.


FDA believes that these documents will enable the reduction of review cycles by helping applicants avoid common
deficiencies that lead to review delays and application cycling, which was one of the FDA’s key goals in2018.

Asphalion has extensive experience in FDA Submissions. Contact us for US regulatory support at

Search News & Events

  • Filter by category


Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting